Biotherapeutics

Date: Wednesday, 27 June 2012 - Thursday, 28 June 2012
Location: London, England

Keynote Speakers

Stefan Karlsson
Professor, Lund University

Jean Boyer
Associate Research Professor, UPenn Medical Center

Herman Waldmann
Professor, University of Oxford

Overview

With a continuing increase in the availability and delivery of biotherapeutics, our speakers will talk you through an array of topics, with a special focus on the immunological and pathological hurdles that must be overcome for a successful effect. Delegates will hear about the basic cellular mechanisms and where along these mechanisms therapeutics will act, the development of therapies into the emerging market, and the technologies required to accurately interpret results. Excitingly, the double-edged sword of immunotherapy will also be discussed. It is a pleasure to announce that Professor Boyer and Professor Karlsson will be speaking alongside Professor Waldmann – the scientist who developed the first academic antibody therapeutic manufacturing facility.

Other conference tracks at this event include Single Use Technologies, Stem Cells and Cell Culture. Registered delegates will have access to all four meetings ensuring a very cost-effective trip.

In addition the event will also host several cutting edge business courses which can be viewed here.

Agenda Topics

Antibodies, Methods for Development and Utility
Biosimilars, Biobetters and Emerging Market Opportunities for Biotherapeutics
Engineering T Cells for Cancer Therapy
Monoclonal Antibodies and Methods for Development
Technologies for Biotherapeutics Production

Sponsorship and Exhibition Opportunities

Exhibition Team,
exhibitors@selectbio.com
+44 (0) 1206 501654

Confirmed Speakers to date

Tudor Arvinte, Chairman and CEO, Therapeomics Inc/University of Geneva
Vanessa Baeriswyl, Postdoc Researcher, EPFL
Wilfried Bakker, Senior Research Scientist, Netherlands Vaccine Institute
Christopher Bravery, Director, Consulting on Advanced Biologicals Ltd
Kerry Chester, Professor, University College London
Mark Cragg, Professor, University of Southampton
Paul Declerck, Professor, Katholieke Universiteit Leuven
Robert Dillman, Executive Medical Director, Hoag Institute for Research and Education
Steffen Goletz, Chief Executive & Scientific Officer, Glycotope GmbH
Robert Hawkins, Professor, University of Manchester
Roy Jefferis, Professor Emeritus, University Of Birmingham
Enal Razvi, Managing Director, Select Biosciences Inc
Tim Sheehy, Director, Promega Corporation
Michael Tovey, Director, Institut Andre Lwoff/INSERM
John Watson, Director, Promega Corporation